---
title: "T&K's subsidiary CKBA's ointment for vitiligo indications has obtained preliminary results from Phase II clinical trials and met the expected goals"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/251401534.md"
description: "T&K Holdings' subsidiary Bochuangyuan's CKBA ointment has achieved preliminary results in Phase II clinical trials for vitiligo, showing good efficacy and safety, meeting the expected goals. These results support the continuation of Phase III clinical trials and will be submitted to the CDE for breakthrough therapy application. As the first innovative drug targeting the T cell fatty acid metabolism pathway, CKBA demonstrates development potential in the field of autoimmune diseases. The company will accelerate the advancement of related clinical trials and basic research"
datetime: "2025-08-04T07:56:03.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/251401534.md)
  - [en](https://longbridge.com/en/news/251401534.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/251401534.md)
---

# T&K's subsidiary CKBA's ointment for vitiligo indications has obtained preliminary results from Phase II clinical trials and met the expected goals

According to the Zhitong Finance APP, T&K (301263.SZ) announced that its holding subsidiary Jiangsu Bochuangyuan Biomedical Technology Co., Ltd. (referred to as "Bochuangyuan") has recently completed data organization and unblinding for the Phase II clinical trial of its independently developed Class I innovative drug CKBA ointment for the treatment of vitiligo. Preliminary results indicate that CKBA ointment shows positive efficacy and good safety in patients with non-segmental vitiligo. The trial results are ideal and meet the expected goals, supporting the continuation of Phase III confirmatory clinical trials. Relevant research data will also be submitted to the CDE for breakthrough therapy application and communication regarding clinical registration in the near future.

The preliminary results of the Phase II clinical trial for CKBA ointment in the treatment of vitiligo have met the expected goals, further validating CKBA as the first-in-class (FIC) innovative small molecule drug targeting T cell fatty acid metabolism pathways, demonstrating significant development potential in the field of autoimmune diseases. The company will accelerate the advancement of Phase III clinical trials for vitiligo and Phase II/III clinical trials for rosacea, while continuing to conduct in-depth basic research on CKBA's targets and mechanisms of action, further expanding its related indications in the field of autoimmune diseases

### Related Stocks

- [301263.CN](https://longbridge.com/en/quote/301263.CN.md)

## Related News & Research

- [08:15 ETHurricane Season 2026: Why Now Is the Time to Secure Travel Insurance](https://longbridge.com/en/news/287218007.md)
- [11:05 ETThe Church of Jesus Christ of Latter-day Saints Commits $25 Million to the UNICEF-led Child Nutrition Fund](https://longbridge.com/en/news/287088476.md)
- [Dunkin' To Give Away 1 Mln Free Coffees For A Day](https://longbridge.com/en/news/286964019.md)
- [20:38 ETHyundai Bioscience Discloses XAFTY®'s IC50 Data for Ebola--"Secured Scientific Evidence for Immediate Treatment"](https://longbridge.com/en/news/287135394.md)
- [16:44 ETInsureMyTrip Urges Travelers to Buy Insurance Early, Before Hurricane Season Begins](https://longbridge.com/en/news/287271339.md)